Navigation Links
Start of Phase I Study for Intranasal Pandemic Influenza Vaccine deltaFLU
Date:7/8/2008

VIENNA, Austria, July 8 /PRNewswire/ -- Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data. In taking this step, the Viennese biotech company sets yet another milestone in the development of effective and safe vaccines.

Aim of Phase I Study

The randomized, double-blind phase I study of the pandemic vaccine deltaFLU will be run at the Department of Clinical Pharmacology, Medical University of Vienna. The aim of phase I study is to analyze the safety and efficacy of the vaccine in healthy volunteers.

Preclinical Data, Pandemic Vaccine

"Our vaccine lacks the pathogenicity factor NS1. Due to this deletion, the vaccine is likely to show a superior safety profile. We are confident that the pandemic deltaFLU vaccine will be tolerated even at high doses," comments Thomas Muster, founder and CEO/CSO of Avir Green Hills Biotechnology.

Outstanding preclinical data show an excellent immune response even against distantly related pandemic H5 strains (cross-protection). Moreover, a long lasting immune response - an important prerequisite for an effective vaccine - was observed.

"We are very pleased about the success of our vaccine in the preclinical studies. The data are superb and exceed our highest expectations," reports Andrej Egorov, who is Vice President for Research at Avir Green Hills Biotechnology and one of the leading experts in the field of live attenuated influenza vaccines.

The novel influenza vaccine deltaFLU

differs from a conventional influenza vaccine in three major characteristics and in the method of production:

1. Nasal Spray

The vaccine is administered intranasally with a spray device instead of being injected into a muscle. This approach offers the major advantage of stimulating the vaccine protection directly at the site of virus entry.

2. Effective Immune Response

Though the vaccine looks like a pathogenic influenza virus to the body, it does not cause disease. However, after intranasal application, the vaccine stimulates a strong immune response, which offers protection against influenza. In other words, the vaccine "fakes" an infection that induces an immune response without causing illness.

3. Cross-Protection

The vaccine can induce an effective immune response against a wide range of influenza virus variants, which is only conditionally possible with conventional vaccines. This cross-reactivity can also provide protection against distantly related "drift variants" of pandemic influenza strains.

4. Cell-Based Production Method

The technology used by Avir Green Hills Biotechnology comprises a modern production method in cell cultures and does not rely on traditional egg-based manufacturing. In addition, Avir Green Hills Biotechnology has optimized the method of reverse genetics, which permits the generation of a vaccine against any potential influenza virus within a very short period of time. This might be essential for a timely response in pandemic situations.

Avir Green Hills Biotechnology Inc.

Avir Green Hills Biotechnology Inc. is a biopharmaceutical company based in Vienna, founded in 2002. Avir Green Hills Biotechnology's core competence is the development of innovative, therapeutic and prophylactic products against viral infections and cancer. "Our strength is our extensive know-how in virology and our network of renowned national and international partners in academia and industry," says Joachim Seipelt, Co-Founder and Vice President for Cooperation at Avir Green Hills Biotechnology.

After completion of phase I clinical trials, Avir Green Hills Biotechnology will start clinical phase II studies with the pandemic and the seasonal deltaFLU vaccines in 2009. Subsequently, Avir Green Hills Biotechnology plans to perform a phase III challenge trial against seasonal influenza, which will allow early proof of efficacy. These studies will provide the basis for phase III field trials leading to market authorization.

Press photos & movies

http://www.greenhillsbiotech.com/news.html

Contact

Isolde Bergmann (Corp. Communications)

mobile: +43-664-8573403

mail: i.bergmann@greenhillsbiotech.com

Avir Green Hills Biotechnology AG

Gersthofer Strasse 29-31

A-1180 Vienna

Austria - Europe

http://www.greenhillsbiotech.com


'/>"/>
SOURCE Avir Green Hills Biotechnology Trade AG
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
2. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
3. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
4. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
5. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
8. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
9. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
10. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
11. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):